Kyle Faget Authors Article on Clinical Trial Agreement Considerations for Pharmaceutical Sponsors
13 January 2022
Foley & Lardner LLP Partner Kyle Faget authored an article, “Clinical Trial Agreement Considerations for Pharmaceutical Sponsors,” for LexisNexis Practical Guidance. The article provides guidance on key provisions when negotiating clinical trial agreements (CTAs) on behalf of pharmaceutical companies.
Faget, co-chair of Foley’s Health Care and Life Sciences Practice Groups, covers topics such as the role of contract research organizations (CROs) in CTA negotiations, preamble, confidentiality, intellectual property, indemnification, subject injury, limitation on liability, and publication rights.
Author(s)
Related Insights
18 September 2024
Health Care Law Today
Medicare Advantage: A Circuit Court Addresses What is (or is not) Material in False Claims Act Cases
On September 13, 2024, the United States Court of Appeals for the Eighth Circuit’s published its much-anticipated decision in United States ex rel. Holt v. Medicare Medicaid Advisors, affirming the Western District of Missouri’s dismissal of a Medicare Advantage case — a win for managed care stakeholders, especially insurance carriers, insurance brokers, and insurance marketing organizations.
18 September 2024
Viewpoints
Unlocking the Power of Equity-Based Incentive Compensation: Basics of Restricted Stock, Restricted Stock Units, and Performance Stock Units
This article is the fourth in our series on equity-based compensation intended to assist employers with answering a common question: What type of equity compensation award is best for our company and our employees?
18 September 2024
Legal News: Employee Benefits Insights
Final Mental Health Parity Rules – Top Five Changes to the Status Quo
The Mental Health Parity and Addiction Equity Act and its implementing regulations and guidance prohibit health insurance policies and group health plans that cover mental health and substance use disorder benefits from imposing limitations on MH/SUD benefits that are less favorable than the limitations imposed on medical/surgical benefits.